In-situ formation of niobium oxide - Niobium carbide - Reduced graphene oxide ternary nanocomposite as an electrochemical sensor for sensitive detection of anticancer drug methotrexate.

Engineering the nanostructure of an electrocatalyst is crucial in developing a high-performance electrochemical sensor. This work exhibits the hydrothermal followed by annealing synthesis of niobium oxide/niobium carbide/reduced graphene oxide (NbO/NbC/rGO) ternary nanocomposite. The oval-shaped NbO/NbC nanoparticles cover the surface of rGO evenly, and the rGO nanosheets are interlinked to produce a micro-flower-like architecture. The NbO/NbC/rGO nanocomposite-modified electrode is presented here for the first time for the rapid and sensitive electrochemical detection of the anticancer drug methotrexate (MTX). Down-sized NbO/NbC nanoparticles and rGO's high surface area provide many active sites with a rapid electron transfer rate, making them ideal for MTX detection. In comparison to previously reported MTX sensors, the developed drug sensor exhibits a lower oxidation potential and a higher peak current responsiveness. The constructed sensors worked analytically well under optimal conditions, as shown by a low detection limit of 1.6 nM, a broad linear range of 0.1-850 µM, and significant recovery findings (∼98 %, (n = 3)) in real samples analysis. Thus, NbO/NbC/rGO nanocomposite material for high-performance electrochemical applications seems promising.

Tailored architecture of molybdenum carbide/iron oxide micro flowers with graphitic carbon nitride: An electrochemical platform for nano-level detection of organophosphate pesticide in food samples.

Herein we report the ternary hybrid nanocomposite of iron oxide @ molybdenum carbide micro flowers decorated graphitic-carbon nitride (Fe3O4@MoC MFs/g-CN), as a catalyst for the detection of organophosphorus pesticide, parathion (PAT), for the first time. The growth of hierarchical nanostructure from the core level will facilitate easy diffusion of analyte and interact more effectively with the reactive catalytic sites. Thus, Fe3O4 NFs architecture was hydrothermally grown over MoC flakes from the core level, which further hybridized with g-CN to ensure electrical conductivity and mechanical stability. Experimental results demonstrate that Fe3O4@MoC MFs/g-CN/GCE has superior catalytic efficacy for PAT reduction. At optimum conditions, the proposed sensor exhibits a low detection limit (7.8 nM), high sensitivity, and wide linear range (0.5-600 µM) toward PAT detection. The satisfactory test results of the food samples indicate that the Fe3O4@MoC MFs/g-CN/GCE sensor can be used as an excellent candidate for real-time PAT detection.

The feasibility of an approximate irregular field dose distribution simulation program applied to a respiratory motion compensation system.

PURPOSE: This study optimized our previously proposed simulation program for the approximate irregular field dose distribution (SPAD) and applied it to a respiratory motion compensation system (RMCS) and respiratory motion simulation system (RMSS). The main purpose was to rapidly analyze the two-dimensional dose distribution and evaluate the compensation effect of the RMCS during radiotherapy. METHODS: This study modified the SPAD to improve the rapid analysis of the dose distribution. In the experimental setup, four different respiratory signal patterns were input to the RMSS for actuation, and an ultrasound image tracking algorithm was used to capture the real-time respiratory displacement, which was input to the RMCS for actuation. A linear accelerator simultaneously irradiated the EBT3 film. The gamma passing rate was used to verify the dose similarity between the EBT3 film and the SPAD, and conformity index (CI) and compensation rate (CR) were used to quantify the compensation effect. RESULTS: The Gamma passing rates were 70.48-81.39% (2%/2mm) and 88.23-96.23% (5%/3mm) for various collimator opening patterns. However, the passing rates of the SPAD and EBT3 film ranged from 61.85% to 99.85% at each treatment time point. Under the four different respiratory signal patterns, CR ranged between 21% and 75%. After compensation, the CI for 85%, 90%, and 95% isodose constraints were 0.78, 0.57, and 0.12, respectively. CONCLUSIONS: This study has demonstrated that the dose change during each stage of the treatment process can be analyzed rapidly using the improved SPAD. After compensation, applying the RMCS can reduce the treatment errors caused by respiratory movements.